PMID- 37310118
OWN - NLM
STAT- MEDLINE
DCOM- 20230615
LR  - 20230625
IS  - 1096-9071 (Electronic)
IS  - 0146-6615 (Linking)
VI  - 95
IP  - 6
DP  - 2023 Jun
TI  - Peptidome-wide association analysis of Epstein-Barr virus identifies epitope 
      repertoires associated with nasopharyngeal carcinoma.
PG  - e28860
LID - 10.1002/jmv.28860 [doi]
AB  - Human leukocyte antigen (HLA) molecules are essential for presenting Epstein-Barr 
      virus (EBV) antigens and are closely related to nasopharyngeal carcinoma (NPC). 
      This study aims to systematically investigate the association between HLA-bound 
      EBV peptides and NPC risk through in silico HLA-peptide binding prediction. A 
      total of 455 NPC patients and 463 healthy individuals in NPC endemic areas were 
      recruited, and HLA-target sequencing was performed. HLA-peptide binding 
      prediction for EBV, followed by peptidome-wide logistic regression and motif 
      analysis, was applied. Binding affinity changes for EBV peptides carrying 
      high-risk mutations were analyzed. We found that NPC-associated EBV peptides were 
      significantly enriched in immunogenic proteins and core linkage disequilibrium 
      (LD) proteins related to evolution, especially those binding HLA-A alleles 
      (p = 3.10 x 10(-4) for immunogenic proteins and p = 8.10 x 10(-5) for core LD 
      proteins related to evolution). These peptides were clustered and showed binding 
      motifs of HLA supertypes, among which supertype A02 presented an NPC-risk effect 
      (p(adj)  = 3.77 x 10(-4) ) and supertype A03 presented an NPC-protective effect 
      (p(adj)  = 4.89 x 10(-4) ). Moreover, a decreased binding affinity toward risk 
      HLA supertype A02 was observed for the peptide carrying the NPC-risk mutation 
      BNRF1 V1222I (p = 0.0078), and an increased binding affinity toward protective 
      HLA supertype A03 was observed for the peptide carrying the NPC-risk mutation 
      BALF2 I613V (p = 0.022). This study revealed the distinct preference of EBV 
      peptides for binding HLA supertypes, which may contribute to shaping EBV 
      population structure and be involved in NPC development.
CI  - (c) 2023 The Authors. Journal of Medical Virology published by Wiley Periodicals 
      LLC.
FAU - Deng, Chang-Mi
AU  - Deng CM
AD  - State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of 
      Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Center 
      for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, People's 
      Republic of China.
FAU - Wang, Tong-Min
AU  - Wang TM
AD  - State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of 
      Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Center 
      for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, People's 
      Republic of China.
FAU - He, Yong-Qiao
AU  - He YQ
AD  - State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of 
      Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Center 
      for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, People's 
      Republic of China.
FAU - Zhang, Wen-Li
AU  - Zhang WL
AD  - State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of 
      Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Center 
      for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, People's 
      Republic of China.
FAU - Xue, Wen-Qiong
AU  - Xue WQ
AD  - State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of 
      Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Center 
      for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, People's 
      Republic of China.
FAU - Li, Dan-Hua
AU  - Li DH
AD  - State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of 
      Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Center 
      for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, People's 
      Republic of China.
FAU - Yang, Da-Wei
AU  - Yang DW
AD  - School of Public Health, Sun Yat-Sen University, Guangzhou, People's Republic of 
      China.
FAU - Wang, Qiao-Ling
AU  - Wang QL
AD  - School of Public Health, Sun Yat-Sen University, Guangzhou, People's Republic of 
      China.
FAU - Liao, Ying
AU  - Liao Y
AD  - State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of 
      Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Center 
      for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, People's 
      Republic of China.
FAU - Diao, Hua
AU  - Diao H
AD  - School of Public Health, Sun Yat-Sen University, Guangzhou, People's Republic of 
      China.
FAU - Jiang, Cheng-Tao
AU  - Jiang CT
AD  - State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of 
      Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Center 
      for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, People's 
      Republic of China.
FAU - Zhang, Jiang-Bo
AU  - Zhang JB
AD  - State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of 
      Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Center 
      for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, People's 
      Republic of China.
FAU - Yuan, Lei-Lei
AU  - Yuan LL
AD  - School of Public Health, Sun Yat-Sen University, Guangzhou, People's Republic of 
      China.
FAU - Chen, Xue-Yin
AU  - Chen XY
AD  - State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of 
      Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Center 
      for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, People's 
      Republic of China.
FAU - Zhou, Ting
AU  - Zhou T
AD  - State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of 
      Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Center 
      for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, People's 
      Republic of China.
FAU - Li, Xi-Zhao
AU  - Li XZ
AD  - State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of 
      Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Center 
      for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, People's 
      Republic of China.
FAU - Zhang, Pei-Fen
AU  - Zhang PF
AD  - State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of 
      Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Center 
      for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, People's 
      Republic of China.
FAU - Zheng, Xiao-Hui
AU  - Zheng XH
AD  - State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of 
      Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Center 
      for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, People's 
      Republic of China.
FAU - Zhang, Shao-Dan
AU  - Zhang SD
AD  - State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of 
      Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Center 
      for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, People's 
      Republic of China.
FAU - Hu, Ye-Zhu
AU  - Hu YZ
AD  - State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of 
      Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Center 
      for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, People's 
      Republic of China.
FAU - Xu, Miao
AU  - Xu M
AD  - State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of 
      Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Center 
      for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, People's 
      Republic of China.
FAU - Zeng, Mu-Sheng
AU  - Zeng MS
AUID- ORCID: 0000-0003-3509-5591
AD  - State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of 
      Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Center 
      for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, People's 
      Republic of China.
FAU - Feng, Lin
AU  - Feng L
AD  - State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of 
      Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Center 
      for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, People's 
      Republic of China.
FAU - Jia, Wei-Hua
AU  - Jia WH
AUID- ORCID: 0000-0002-0528-8715
AD  - State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of 
      Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Center 
      for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, People's 
      Republic of China.
AD  - School of Public Health, Sun Yat-Sen University, Guangzhou, People's Republic of 
      China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Med Virol
JT  - Journal of medical virology
JID - 7705876
RN  - 0 (Epitopes)
RN  - 0 (Histocompatibility Antigens Class II)
SB  - IM
MH  - Humans
MH  - Epitopes
MH  - Herpesvirus 4, Human/genetics
MH  - *Epstein-Barr Virus Infections/complications/genetics
MH  - Nasopharyngeal Carcinoma/genetics
MH  - Histocompatibility Antigens Class II
MH  - *Nasopharyngeal Neoplasms/genetics
OTO - NOTNLM
OT  - Epstein-Barr virus
OT  - human leukocyte antigen
OT  - nasopharyngeal carcinoma
OT  - peptide-binding motif
OT  - peptidome-wide association
EDAT- 2023/06/13 13:12
MHDA- 2023/06/15 06:41
CRDT- 2023/06/13 09:03
PHST- 2023/05/29 00:00 [revised]
PHST- 2023/02/25 00:00 [received]
PHST- 2023/05/30 00:00 [accepted]
PHST- 2023/06/15 06:41 [medline]
PHST- 2023/06/13 13:12 [pubmed]
PHST- 2023/06/13 09:03 [entrez]
AID - 10.1002/jmv.28860 [doi]
PST - ppublish
SO  - J Med Virol. 2023 Jun;95(6):e28860. doi: 10.1002/jmv.28860.